神经分泌生物科学（NBIX）周二盘中大涨16.71%，引发投资者广泛关注。尽管公司最新公布的季度每股收益不及预期，但强劲的营收表现和分析师的积极评价推动了股价的大幅上涨。
根据公司财报，截至3月31日的季度调整后每股收益为8美分，远低于分析师平均预期的54美分。然而，公司的营收表现亮眼，同比增长11.1%，达到5.726亿美元，超过分析师预期的5.5933亿美元。这一营收增长显示了公司产品的市场需求依然强劲。
华尔街分析师对神经分泌生物科学保持乐观态度。加拿大皇家银行（RBC）将该公司的目标价从137美元上调至145美元，显示出对公司长期发展前景的信心。目前，分析师对该公司股票的平均评级为"买入"，12个月目标价中位数为160美元。分析师的积极评价有效抵消了季度业绩不及预期的负面影响，成为推动股价上涨的重要因素。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.